pexels-rodnae-productions-6129900.jpg

Committed to Finding New Treatments for Glioblastoma


Our team of internationally acclaimed neurologists and patented technology offer a promising combination.

If you’re one of the 10,000 people in the USA diagnosed or a family member of one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. Nearly all patients diagnosed die within 12-18 months.

 

Some cancers, including brain cancer, have been historically underfunded despite the grim prognosis for those patients diagnosed. No doubt this is a direct corollary to why some cancers, like glioblastoma, have relatively few to no treatment options.

 

Research shows that 80% of the instances of recurrence, which are inevitable, appear in the tissue surrounding the resection cavity. The blood-brain barrier imposes biological limitations that make it easier for cancerous cells to invade the brain than it is for them to exit the brain and metastasize elsewhere. That sounds almost encouraging until you begin to discuss drug delivery: most therapeutics have high molecular weights beyond the range suitable for drug transport. Check point inhibitors which modulate biological pathways are generally effective in the treatment of most diseases: not so for glioblastoma.

 

Targeted delivery using nanoparticles to transport highly selective inhibitors across the blood-brain barrier remains the next frontier for treatment. “Glioblastoma requires an arsenal to combat,” said Dr. TBD, “we view the combination of improved targeting with localized delivery of specific inhibitors designed to penetrate the blood-brain barrier, potentially with radioactivated nanoparticles, as a novel modality worthy of further exploration.” GCT has recently acquired two patents for medicinal compounds that are known to cross the blood-brain barrier: PI3K and Vps34 act in mechanistically distinct manners as potent inhibitors of pathways commonly associated with cancers.

pexels-anna-shvets-4226119.jpg

“Global Cancer Technology has the only radioactivated drug transport technology of its kind in the world."
- Dr. Santosh Kesari, John Wayne Cancer Institute.

Dr. Ekokobe Fonkem, director of neuro-oncology and an associate professor and chair in the Department of Neurology at Barrow Neurological Institute.

The future of treatment

“Indeed, transport across the blood-brain barrier has been a fantasy of neurologists for some time. Delivering inhibitors like PI3K and Vps34 directly to the brain tumor with timed precision is an incredibly exciting approach, one that I’m personally honored to be involved in exploring.”

pexels-anna-shvets-4483327.jpg

Consider making an investment today that may change the future of Glioblastoma patients.

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

The other inhibitor acquired by GCT targets Vps34, a PI3K isoform known to affect cellular mobility and autophagy. Inhibitors of Vps34 have been shown to impede the movement of cancerous cells and their ability to induce the “suicide” of surrounding healthy cells.

 

Deducing how these inhibitors behave in glioblastoma patients requires further research. The ability to penetrate the blood-brain barrier is, in of itself, a tremendous advantage. Uilizing that advantage to commercialize the targeted delivery of a therapeutic payload directly to the glioma mass within the brain is where GCT is focusing its efforts.

 

To sum up – there is an urgent need for novel treatments of glioblastoma. And several are in development.

 

Global Cancer Technology has the only radioactivated drug transport technology of its kind in the world. When successfully commercialized, the company will significantly impact cancer treatment outcomes and establish itself as a leader in this cancer treatment delivery market,” stated Dr. Santosh Kesari, world-renowned Neuro-Oncologist at John Wayne Cancer Institute.

surgery.jpg

Cancer Treatment

Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as Barrow Neurological Institute, UCSD and the University of Washington, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Learn more about Global Cancer Technology's remote-controlled cancer drug delivery platform by clicking here.

pexels-artem-podrez-5726794.jpg

INVEST NOW

$500

Minimum Investment

$2.00

Share Price

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

Dr. Chad Quarles, professor Barrow Neurological Institute

Blocking cancer in its tracks

“Phosphatidylinositol 3-kinase (PI3K) is associated with cellular processes including cell death, protein synthesis and metabolism. PI3K has been shown to block this aberrant activity. Given the number of multimodal imaging methods that we are currently deploying to improve disease characterization and detection, particularly for brain cancers, we are eager to study how this inhibitor affects the progression of brain cancer.”

 

Need more info before becoming an investor?

Following the close of an investment round earlier this year at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. Preferred pricing available for investments of $10K or more. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment for both COVID-19 and cancer.

Subscribe to get notified of our progress.

  • Facebook
  • LinkedIn
  • YouTube

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.

 

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE SECURITIES ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.

 

SUBSCRIBERS WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.

 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

 

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

 

THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.

© 2021 by Global Cancer Technology